--you're right. I think that's exactly what happened. The irony is neither side is getting what it wanted.
The “smaller provinces” with smaller budgets wanted to get good-quality pharmaco-economics, and I would submit to you that they aren't.
The larger provinces were hoping that no would be no. The fact of the matter is, it isn't that no is no and yes is maybe; they are in fact providing many of the drugs that this group recommends not to provide, because they see in their own provinces that those decisions aren't withstandable from a scientific perspective and a pharmaco-economic perspective.
Yes, I think everybody wanted something, and nobody's getting what they wanted out of it, which is why the Atlantic provinces continue to have an Atlantic common drug review. They've actually come together to meet themselves, and the provinces have continued to keep their own processes going.
I don't think we're any farther ahead with CDR than we were before, and I don't think continuing to keep something going that nobody likes and nobody is getting what they want from is a good spending of $5.1 million. I would rather see—